1. Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

3. HF Concerns in T2DM

4. How Should HF Be Evaluated in Patients With T2DM?

5. The Role of DPP-4 Inhibition in GLP-1 Activity

6. Experimental Evidence Supporting Beneficial Effects of DPP-4 Inhibition in HF

7. DPP-4 Inhibitor CV Outcomes Trials: Study Designs

8. DPP-4 Inhibitor CV Outcomes Trials: Key Inclusion and Exclusion Criteria

9. DPP-4 Inhibitor CV Outcomes Trials: Prespecified CV Endpoints

10. DPP-4 Inhibitor CV Outcomes Trials: Primary Endpoint

11. DPP-4 Inhibitor CV Outcomes Trials: Adjudicated Endpoints

12. DPP-4 Inhibitor CV Outcomes Trials: Hospitalization for HF

13. DPP-4 Inhibitors: EXAMINE vs SAVOR vs TECOS Primary Endpoint by History of HF

14. EXAMINE HF Analysis: Time to Composite of CV Death and Hospitalization for HF by History of HF

15. HF Endpoints in CV Outcomes Studies

17. DPP-4 Inhibitor CV Outcomes Trials: Summary

18. CNODES, A Multicenter Observational Study of Incretin-Based Drugs and HF

19. Retrospective Cohort Study of HF in T2DM: Risk for Hospitalized HF

20. FDA Warning and Precaution Labels for the DPP-4 Inhibitors as They Relate to Cardiac Failure ARE NOT EVIDENCE BASED

21. EMA Labels for the DPP-4 Inhibitors and Cardiac Failure ARE EVIDENCE BASED

22. Summary

23. Abbreviations

24. Abbreviations (cont)